Filing Flows › Aytu Biopharma (AYTU) › Q4 FY26 › vs Q4 FY25
Aytu Biopharma (AYTU) Q4 FY26 vs Q4 FY25 (year over year)
Aytu Biopharma's revenue rose $971K (+6%) from $15.1M in Q4 FY25 to $16.1M in Q4 FY26.
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart draws each line against Q4 FY25, the increases inside each band.
Margins
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Free cash flow margin | 27.3% | 18.4% | +8.9 pts |
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $16.1M | $15.1M | $971K | +6% |
| Other income, net | $773K | −$11.8M | $12.6M | — |
| Net loss | $15K | $19.8M | −$19.8M | -100% |
| Costs & expenses | $16.9M | $35.0M | −$18.1M | -52% |
| Operating costs | $16.9M | $22.8M | −$5.9M | -26% |
| Income tax | $11K | $437K | −$426K | -97% |
| Cost of revenue | $5.7M | $4.9M | $816K | +17% |
| Sales & marketing | $6.1M | $4.8M | $1.3M | +28% |
| General & admin | $4.3M | $3.7M | $609K | +16% |
| Other operating costs | $761K | $9.2M | −$8.4M | -92% |
| Operating cash sources | $4.4M | $22.6M | −$18.2M | -80% |
| Depreciation & amortization | $1.1M | $1.5M | −$343K | -23% |
| Share-based compensation | $146K | $113K | $33K | +29% |
| Working capital & other | $3.2M | $21.0M | −$17.9M | -85% |
| Net loss absorbed | $15K | $19.8M | −$19.8M | -100% |
| Operating cash flow | $4.4M | $2.8M | $1.6M | +57% |
| Free cash flow (OCF − capex) | $4.4M | $2.8M | $1.6M | +58% |
| Capital expenditures | $12K | $17K | −$5K | -29% |
Questions
How much did Aytu Biopharma's revenue grow year over year in Q4 FY26?
Aytu Biopharma's revenue rose $971K (+6%) from $15.1M in Q4 FY25 to $16.1M in Q4 FY26.